Navigation Links
Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations
Date:9/16/2008

ome technology licensed from Pevion Biotech Ltd. Mymetics' vaccine approach focuses on eliciting immune protection capable of interfering with late events of pathogen transmission, a generally accepted approach coupled, uniquely and most importantly, with early events of pathogen transmission, such as preventing virus entry across the mucosal tissues, the primary entry door of most pathogens. Virosomes are lipidic vesicles derived from influenza virus membrane that are non-replicative antigen carriers which possess intrinsic systemic and mucosal adjuvant properties. Virosomes are approved in 42 countries and have been used since 1994 for two vaccines in over 40 million doses with no significant side effects. The Company's disease focus presently includes malaria and the human immunodeficiency virus.

For further information regarding the Company and its mucosal approach, please visit http://www.mymetics.com.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are "forward-looking statements."Such forward-looking statements are sometimes identified by words such as "intends,""anticipates,""believes,""expects" and "hopes."The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings
'/>"/>

SOURCE Mymetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
4. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407
8. Researchers Report First Successful Treatment of Chronic Traumatic Brain Injury
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
11. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, today ... and their first West Coast location in San ... in Boston , and will house product development, ... Southern California office will be located at 1000 ... demands of customers nationwide.  Both new locations will be operational ...
(Date:9/16/2014)... Resources Group finds that the rheumatoid arthritis (RA) disease-modifying antirheumatic drug ... billion in 2023 in the United States , ... Italy , Spain , the ... TNF-alpha inhibitors will remain the leading drug class in both sales ... constrained and patient shares will decline due to the uptake of ...
(Date:9/16/2014)... 16, 2014  Formex, LLC ("Formex"), a ... Mr. Greg Weilersbacher joined Formex as Director of ... Greg Weilersbacher has over ... expertise in Quality Assurance, Facility Validation, GMP ... brings to Formex a diverse wealth of ...
Breaking Medicine Technology:QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
... US Phase II Clinical Trials for Organ Transplantation, ... announces positive Phase I clinical results for,its transplantation ... clinical trials for organ transplantation. , Today LifeCycle ... I clinical trial program of LCP-Tacro, a,proprietary, once-daily ...
... Hemispherx Biopharma, Inc.,(AMEX: HEB), a biopharmaceutical company ... new drug entities for pandemic,disease threats, announced ... therapeutic product candidate Alferon-LDO in,combating highly pathogenic ... Alferon-LDO is a low-dose experimental oral formulation,of ...
Cached Medicine Technology:LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 2LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 3Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 2Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 3Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 4
(Date:9/16/2014)... (PRWEB) September 16, 2014 SAMHSA, the federal ... mission a reduction of the impact of substance abuse and ... on the SAMHSA website in September is National Recovery Month, ... honor the gains made by those individuals in recovery. ... to addiction treatment in an effort to help those with ...
(Date:9/16/2014)... Using a pain clinic as a testing ground, researchers ... first popularized by Toyota in Japan can substantially reduce ... interns and residents. , In a report on the ... Medicine , the researchers adopted the so-called "Just-in-Time" training ... service industries to stem waste and keep complicated operations ...
(Date:9/16/2014)... R.I. (PRWEB) September 16, 2014 As ... Sunday, Sept. 14, through Saturday, Sept. 20, Amica ... sure children are safe and secure while in the ... the National Traffic Highway Safety Administration (NHTSA), 20 ... not read the instruction manual when installing child restraints. ...
(Date:9/16/2014)... 2014 Regulatory intelligence (RI), the ... has become a crucial skill for regulatory professionals ... sectors. Regulatory Intelligence 101 , new from ... serves as an essential guide to the basics ... examines available regulatory intelligence tools, both free and ...
(Date:9/16/2014)... Illegal drug use among teens in the United States is ... Encouragingly, the new study also found that alcohol use, ... people between the ages of 12 and 17 also dropped ... people aged 12 and older across the United States revealed ... among this age group also dropped from 8.9 percent to ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Booklet Offers Tips During Recovery Month 2Health News:Narconon Arrowhead Booklet Offers Tips During Recovery Month 3Health News:Patients waiting too long to see doctor? Try 'just-in-time' management methods, researchers urge 2Health News:Amica Offers Tips During Child Passenger Safety Week 2Health News:RAPS Publishes Regulatory Intelligence 101 Book 2Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2
... apply the chemicals, study shows , THURSDAY, June 18 ... the normal risk of developing a precancerous blood disorder, ... undetermined significance) and characterized by an abnormal level of ... can lead to multiple myeloma, a cancer of the ...
... ... term, the continent’s healthcare leadership must be strengthened and expanded at the individual, institutional, ... ... -- To improve health outcomes in Africa over the long term, the continent’s healthcare ...
... up at night worrying whether they are going to develop diabetes ... middle age is a lifetime away. As it ... School of Medicine have found that young adults (18 to 30 ... treadmill test -- are two to three times more likely to ...
... Arnhem, June 2009 The 4th ESU Master class ... the European School of Urology (ESU) on 27-28 June ... The format consists of three modules. Module 1 is ... ,Immunotherapy and targeted therapies, and module 3 ,Systemic cytotoxic ...
... (OTC Bulletin Board: BHRT) a company committed to delivering ... treat heart failure and cardiovascular diseases announced today that ... systems at the American Association of Heart Failure Nurses ... place from June 25 - 27, 2009 at the ...
... , ... present never-before released results from two annual surveys at the upcoming DIA Meeting in ... ... for clinical trials information, will present never-before released results from two annual surveys aimed ...
Cached Medicine News:Health News:Pesticides Linked to Blood Disorder 2Health News:Accordia Global Health Foundation Calls for Greater Investment to Build African Healthcare Leadership 2Health News:Accordia Global Health Foundation Calls for Greater Investment to Build African Healthcare Leadership 3Health News:Aerobically unfit young adults on road to diabetes in middle age 2Health News:4th ESU master class on medical treatment for urological cancer held in Barcelona, Spain 2Health News:Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 2Health News:Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 3Health News:CenterWatch to Introduce Key Findings from Surveys on Physician Referrals to Clinical Trials and Clinical Trial Volunteer Experiences at DIA Meeting 2
Lombart clip-on occluder...
9 inch double ended with one end black and the other end with 49 holes...
Double Ended Occluders...
Long handle occluders are approximately 9 inches long....
Medicine Products: